BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.

NASDAQ:BVXV

BiondVax Pharmaceuticals Ltd.

Last Close

1.35

06/09 19:59

Market Cap

4.97M

Beta: 2.47

Volume Today

22.67K

Avg: 41.50K

PE Ratio

0.59

PFCF: −3.53